Liquidia (NASDAQ:LQDA) CAO Sells $65,807.00 in Stock

Liquidia Corporation (NASDAQ:LQDA) CAO Dana Boyle sold 1,580 shares of the firm’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $41.65, for a total value of $65,807.00. Following the completion of the transaction, the chief accounting officer owned 178,848 shares in the company, valued at $7,449,019.20. The trade was a 0.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Dana Boyle also recently made the following trade(s):

• On Monday, January 12th, Dana Boyle sold 11,047 shares of Liquidia stock. The stock was sold at an average price of $37.43, for a total transaction of $413,489.21.
• On Monday, December 1st, Dana Boyle sold 303 shares of Liquidia stock. The shares were sold at an average price of $32.19, for a total transaction of $9,753.57.

Liquidia Price Performance

Shares of NASDAQ:LQDA opened at $42.39 on Friday. The firm has a 50 day moving average of $35.45 and a 200-day moving average of $27.90. Liquidia Corporation has a 12 month low of $11.26 and a 12 month high of $44.27. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19. The stock has a market capitalization of $3.69 billion, a PE ratio of -29.44, a PEG ratio of 1.21 and a beta of 0.48.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.41. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The business had revenue of $54.34 million for the quarter, compared to analysts’ expectations of $18.86 million. Liquidia’s revenue for the quarter was up 1106.7% compared to the same quarter last year. On average, equities research analysts predict that Liquidia Corporation will post -1.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Liquidia

Several hedge funds have recently added to or reduced their stakes in LQDA. NewEdge Advisors LLC acquired a new position in Liquidia in the 2nd quarter valued at approximately $25,000. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Liquidia in the third quarter worth $30,000. FNY Investment Advisers LLC acquired a new stake in Liquidia in the third quarter valued at $34,000. Steward Partners Investment Advisory LLC raised its position in Liquidia by 24.0% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company’s stock worth $77,000 after purchasing an additional 1,200 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in Liquidia by 281.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock worth $83,000 after buying an additional 4,927 shares during the period. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Jefferies Financial Group upped their price objective on Liquidia from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, January 13th. Wall Street Zen cut shares of Liquidia from a “buy” rating to a “hold” rating in a report on Sunday, January 18th. HC Wainwright raised their price target on shares of Liquidia from $35.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Needham & Company LLC upped their price objective on shares of Liquidia from $36.00 to $52.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Finally, Zacks Research upgraded shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 13th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $39.67.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).